Craft
Bellicum Pharmaceuticals

Bellicum Pharmaceuticals

Revenue

$500 K

FY, 2020

Market Capitalization

$9.6 M

2023-01-31

Bellicum Pharmaceuticals Summary

Company summary

Overview
Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. It designs new treatments for various forms of cancer, including both hematological cancers and solid tumors. The company offers CAR-T and CAR-NK cell therapies which are an approach in which a patient’s or donor’s T cells or NK cells, respectively, are genetically modified to carry chimeric antigen receptors, or CARs.
Type
Public
Status
Active
Founded
2004
HQ
Houston, TX, US | view all locations
Website
http://www.bellicum.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Rick Fair

    Rick Fair, President and Chief Executive Officer, Director

  • Atabak Mokari
  • Jaa Roberson

    Jaa Roberson, Vice President, Human Resources

  • Thierry Darcis

    Thierry Darcis, General Manager of Europe

LocationsView all

4 locations detected

  • Houston, TX HQ

    United States

    2130 W Holcombe Blvd #800Houston

  • Houston, TX

    United States

    2710 Reed Rd #160

  • Houston, TX

    United States

    3730 Kirby Dr #1200-A

  • South San Francisco, CA

    United States

    Building 83, 611 Gateway Blvd #820

Bellicum Pharmaceuticals Financials

Summary financials

Revenue (Q3, 2022)
$1.0M
Net income (Q3, 2022)
($7.2M)
Cash (Q3, 2022)
$28.8M
EBIT (Q3, 2022)
($7.2M)

Footer menu